Actinium Pharmaceuticals, Inc.
ATNM
$1.39
-$0.13-8.55%
| Weiss Ratings | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.53 | |||
| Price History | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.03% | |||
| 30-Day Total Return | 13.01% | |||
| 60-Day Total Return | -2.80% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 10.32% | |||
| 1-Year Total Return | -84.28% | |||
| 2-Year Total Return | -84.89% | |||
| 3-Year Total Return | -73.77% | |||
| 5-Year Total Return | -75.46% | |||
| 52-Week High % Change | -85.16% | |||
| 52-Week Low % Change | 47.69% | |||
| Price | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.24 | |||
| 52-Week Low Price | $1.03 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | May 14, 2024 | |||
| Valuation | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 47.42M | |||
| Enterprise Value | -23.91M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.27 | |||
| Earnings Per Share Growth | -30.75% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.45 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.39 | |||
| Enterprise Value/EBITDA (TTM) | 0.58 | |||
| Enterprise Value/EBIT | 0.57 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 31.20M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 646 677 3870 | |||
| Address | 100 Park Avenue New York, NY 10017 | |||
| Website | www.actiniumpharma.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -33.25% | |||
| Return on Equity | -- | |||
| Income Statement | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -41.46M | |||
| EBIT (TTM) | -42.12M | |||
| Net Income (TTM) | -38.24M | |||
| Net Income Avl. to Common (TTM) | -38.24M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 28.66% | |||
| EPS Diluted (TTM) | -1.27 | |||
| EPS Diluted Growth (Q YOY) | 37.28% | |||
| Balance Sheet | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 72.90M | |||
| Cash Per Share (Q) | $2.34 | |||
| Total Current Assets (Q) | 74.51M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 32.76M | |||
| Current Ratio (Q) | 9.144 | |||
| Book Value Per Share (Q) | $1.05 | |||
| Total Assets (Q) | 76.90M | |||
| Total Current Liabilities (Q) | 8.15M | |||
| Total Debt (Q) | 1.57M | |||
| Total Liabilities (Q) | 44.14M | |||
| Total Common Equity (Q) | 32.76M | |||
| Cash Flow | ATNM - AMEX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.00K | |||
| Cash from Financing (TTM) | 29.32M | |||
| Net Change in Cash (TTM) | -3.76M | |||
| Levered Free Cash Flow (TTM) | -23.35M | |||
| Cash from Operations (TTM) | -33.07M | |||
